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To evaluate the efficacy of an intranasal, inactivated, virosomal subunit influenza vaccine for prevention of
new episodes of acute otitis media (AOM) in children with recurrent AOM, 133 children aged 1–5 years were
randomized to receive the vaccine ( ) or no vaccination ( ). During a 6-month period, 24 (35.8%)np 67 np 66
vaccine recipients had 32 episodes of AOM; 42 (63.6%) control subjects had 64 episodes. The overall efficacy
of vaccination in preventing AOM was 43.7% (95% confidence interval, 18.6–61.1; ). Children vac-Pp .002
cinated before influenza season had a significantly better outcome than did those vaccinated after the onset
of influenza season. The cumulative duration of middle ear effusion was significantly less in vaccinated children
than in control subjects. Data suggest that the intranasal virosomal influenza vaccine might be considered
among the options for the prevention of AOM in children !5 years old with recurrent AOM.
Recurrent acute otitis media (AOM) is common in in-
fants and children, and its possible sequelae make pre-
vention desirable [1]. Chemoprophylaxis, immunopro-
phylaxis, surgery, and the control of environmental risk
factors have been proposed as preventive measures, but
the first of these has long been considered the best
option because of its ease and effectiveness in reducing
the incidence of AOM [2]. However, its use has been
questioned because of the risk of nasopharyngeal col-
onization by drug-resistant bacteria [3–5].
The emergence of drug-resistant bacteria has in-
creased the importance of immunoprophylaxis, the aim
of which is to provide protection against the major
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pathogens known to be direct or indirect causal agents
of AOM [6, 7]. The evidence that viral infections are
associated with many, if not most, episodes of AOM
[8] has caused immunoprophylaxis against respiratory
viruses to receive growing attention.
It has been shown that administration of standard
parenteral inactivated influenza vaccine decreased the
incidence of AOM by approximately one-third in chil-
dren attending day care centers during a community
outbreak of influenza [9–11]. Live, attenuated, cold-
adapted intranasal influenza vaccine was shown to be
effective in reducing the number of episodes of febrile
otitis media by 30% among healthy children without a
history of ear disease [12, 13]. However, although live
attenuated influenza vaccine is effective and readily ac-
ceptable, some researchers have expressed concerns
about the use of living influenza particles in humans
[14–16].
Virosomes are small, suspended spheres with a lipid
bilayer that can serve as a vehicle for solubilized viral
proteins and that may improve antigen immunogen-
icity without causing toxicity [17]. An influenza vaccine
has been developed for intranasal administration, which
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is formed by inserting purified hemagglutinin from influenza
strains into virosomes and is adjuvanted with Escherichia coli
heat-labile toxin [18, 19]. In adults, it is immunogenic and is
as safe as the classical inactivated vaccines, and it may be an
alternative to live attenuated vaccine [20]. In the present study,
we evaluated the efficacy of this intranasal virosomal influenza
vaccine for the prevention of new episodes of AOM in children
with recurrent AOM.
METHODS
Vaccine. The intranasal, inactivated, virosomal subunit in-
fluenza vaccine (Nasalflu) was supplied by Berna Biotech at the
beginning of November 1999 and stored at 2C–8C. Each dose
consisted of 7.5 mg of purified hemagglutinin from each of the
three 1999–2000 World Health Organization–recommended
influenza strains (A/Beijing/262/95-like, H1N1; A/Sydney/5/
97-like, H3N2; and B/Beijing/184/93-like), coupled with a re-
constituted immunopotentiating influenza virosome and ad-
juvanted with 2 mg of E. coli heat-labile toxin. The special
delivery spray consisted of a 2-shot large-particle aerosol de-
signed to deliver one 0.1-mL aliquot of vaccine per nostril, for
a total volume of 0.2 mL.
Population and eligibility criteria. Children aged 1–5
years with a history of recurrent AOM, defined as 3 episodes
in the preceding 6 months or 4 episodes in the preceding 12
months, with the most recent episode of AOM in the previous
2–8 weeks, were included in the study. The episodes were doc-
umented by medical records, with 2 episodes documented
by symptoms and otoscopy and tympanometry findings. The
children had to be free of AOM, but they could have otitis
media with effusion (OME). The exclusion criteria were acute
febrile illness (rectal temperature, 38.1C), severe atopy, any
previous influenza vaccination, acquired or congenital im-
munodeficiency, recent administration of blood products, cleft
palate, chronically ruptured eardrum, obstructive adenoids,
sleep apnea syndrome, and placement of tympanostomy tubes.
Study design. This single-center, prospective, randomized,
single-blind study was conducted in Italy during the 1999–2000
influenza season. The study protocol was approved by the ethics
committee of the University of Milan, the research was con-
ducted in accordance with the guidelines for human experi-
mentation specified by the authors’ institutions, and a parent
or legal guardian was required to provide written informed
consent for each child. The single-blind design was chosen
because, for technical reasons, the preparation of a placebo
containing all the components of the formulation except in-
fluenza antigens was impossible.
Intervention. Children were assigned randomly 1:1 to the
vaccine group or to the control group. The vaccine was ad-
ministered in 2 doses on days 1 and 8 (1 day). In order to
ensure investigator blinding, the assignment and vaccine ad-
ministration were performed by 2 investigators (R.C. and S.G.),
and the parents were instructed not to discuss group assignment
with the investigator responsible for the clinical and otological
follow-up (P.M.), who remained blinded to group assignment
until the end of the follow-up period.
Safety. The parents were asked to record daily on a diary
card, for the 4 days after the administration of each dose of
vaccine, the child’s temperature and the occurrence of systemic
symptoms (rectal temperature of 38.1C, shivering, irritabil-
ity, earache, cough, nausea, and diarrhea) and nasal symptoms
(itchy, stuffy, or runny nose and sneezing). Parents rated their
satisfaction with the safety and tolerability of the vaccine as
“bad,” “good,” or “very good.”
Study procedures. Children were examined at study entry
and every 4–6 weeks for 25 weeks. To overcome the possible
underreporting of disease in vaccine recipients related to a par-
ent’s feeling that the vaccine was giving protection, all the fam-
ilies were called twice per week by telephone to inquire about
day-to-day status and to remind parents of the possibility of
freely contacting an investigator at any time of day to arrange
an extra visit within 24 h whenever the child developed symp-
toms of respiratory tract illness. At each visit, a history of
infection between the 2 visits was obtained, and pneumatic
otoscopy (Welch Allyn, model 20200) and tympanometry (Am-
plaid 770; Amplifon) were performed, together with a complete
physical examination [21, 22]. The procedures were always car-
ried out by the same investigator (P.M.), who was validated in
the use of the instruments.
The diagnosis of AOM was made on the basis of the presence
of any combination of the following findings: fever, earache,
irritability, and hyperemia or opacity accompanied by bulging
or immobility of the tympanic membrane; tympanometry as-
sisted in establishing the presence of effusion in doubtful cases.
The diagnosis of OME was made on the basis of impaired
mobility, opacification, fullness or retraction of the eardrum
associated with a tympanogram with a flat tracing, and the
absence of signs and symptoms of acute infection.
Whenever AOM was diagnosed, amoxicillin plus clavulanic
acid (50 mg/kg per day of amoxicillin) was given for 10 days.
No other treatments were allowed for AOM, except for acet-
aminophen in the case of fever. Bilateral ear involvement was
considered a single episode. Relapse and recurrence were de-
fined as reappearance of signs and symptoms of AOM4 days
after the end of therapy or 5–14 days after the end of therapy,
respectively. If 2 episodes of AOM occurred within a 6-week
period, chemoprophylaxis with amoxicillin (20 mg/kg per day)
was administered.
Analysis. The primary outcome measure was the occur-
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Table 1. Characteristics of 133 consecutive children who received intranasal virosomal






Male sex 38 (56.7) 42 (63.6)
Age
Mean months  SD 32.6  14.6 36.2  15.9
24 months 27 (40.3) 22 (33.3)
124 months 40 (59.7) 44 (66.7)
Enrolled before influenza period 32 (47.8) 33 (50.0)
Breast-feeding 59 (88.1) 58 (87.9)
Duration of breast-feeding, mean months  SD 5.7  3.4 5.4  3.1
Prolonged use of pacifier 13 (19.4) 13 (19.7)
1 older sibling 23 (34.3) 22 (33.3)
No. of cohabiting family members, mean  SD 3.6  0.7 3.5  0.5
Passive exposure to smoking 10 (14.9) 9 (13.6)
Day care attendance 50 (74.6) 54 (81.8)
Hospitalization in the previous 3 months 1 (1.5) 3 (4.5)
Time since last episode of AOM, median days (range) 21 (14–45) 30 (15–60)
Presence of otitis media with effusion 59 (88.0) 59 (89.4)
Previous adenoidectomy 0 2 (3.0)
NOTE. Data are no. (%) of patients, unless otherwise specified. Differences were NS. AOM, acute otitis
media.
rence of AOM within the 6-month period. Secondary outcome
measures were the occurrence of febrile respiratory illnesses,
the use of antibiotics, and the estimated proportion of time
with bilateral OME. The analyses were conducted for the intent-
to-treat population. The sample-size determination was based
on data from the literature [9]. On the basis of those data, the
percentage of control subjects who did not respond to the
vaccine (i.e., those with AOM) was estimated to be 29.4% (55
of 187 subjects). Assuming that the expected percentage of
vaccine recipients with no response to the vaccine would have
been ∼12% (i.e., ∼40% of the percentage among control sub-
jects) and assuming the use of a 1-tailed test with ap 0.05
and , we sought a sample size of 66 children in eachbp 0.20
group.
To evaluate the efficacy of the vaccine in relation to the
influenza season, the vaccine recipients were stratified into 2
groups: those who had completed vaccination at least 1 week
before the start of influenza season and those who were in-
completely or not vaccinated when the season began. The in-
fluenza season was defined as the period from the date of the
first isolation of influenza virus through the date of the last
isolation of influenza virus in Italy, as determined by the sur-
veillance system that collected clinical reports from sentinel
physicians, integrated with virological surveillance (information
is available at http://www.influnet.it). The occurrence of AOM
was also analyzed with respect to the possible influence of ep-
idemiological variables. A finding of OME in the same ear on
2 consecutive occasions was considered to indicate its persist-
ence during the interval; when OME was present at one ex-
amination and absent in the other, it was considered to have
been present for half of the intervening period.
Statistical analysis. The statistical comparisons were made
by nonparametric or exact tests with SAS software, version 8
(SAS Institute). was considered statistically significant.P ! .05
The categorical data were summarized by counts and percent-
ages and compared by the x2 test with Yates’ correction for 4-
fold tables; if the sample was too small, Fisher’s exact t test was
used. The risk of the appearance of AOM was compared be-
tween groups by calculating protective efficacy and its 95%
confidence interval. A logistic multivariate model was used to
investigate whether, in addition to being influenced by the
method of treatment, outcome was influenced by age, sex, day
care attendance, or passive exposure to smoking. A forward
stepwise selection was used with a value of . The adversePp .10
event data are presented in terms of the rates of reporting
frequency on a per-patient basis.
RESULTS
Population. Table 1 summarizes the characteristics of the
133 consecutive children enrolled from 9 November 1999
through 18 January 2000; of these 133, a total of 67 were
vaccinated, and 66 were assigned to the control group. The
groups were similar, without significant statistical differences,
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Table 2. Effectiveness of influenza vaccine, as indicated by the occurrence of febrile res-
piratory illness and acute otitis media (AOM) and the receipt of antibiotic treatment in children








Febrile respiratory illnessa 55 (82.1) 63 (95.5) 13.2 .03
Receipt of 1 course of antibiotics 26 (38.8) 42 (63.6) 38.9 .007
1 episode of AOM 24 (35.8) 42 (63.6) 43.7 .002
1 episode of AOM 18 (26.9) 26 (39.4) 31.8 .21
2 episodes of AOM 6 (9.0) 16 (24.2) 63.1 .03
NOTE. Data are no. (%) of patients, unless otherwise specified.
a Temperature 38.1C.
Table 3. Occurrence of acute otitis media (AOM), by timing of vaccination and influenza season,
among children who received influenza vaccine to prevent AOM.
Time of enrollment, patient group









Vaccine recipients (n p 32) 6 (18.8)a 2 (6.3) 2 (6.3)b 2 (6.3)
Control subjects (n p 33) 17 (51.5) 2 (6.0) 10 (30.3) 5 (15.2)
Reduction, % (P) 63.6 (.01) — 79.5 (.02) 58.9 (.42)
During influenza season
Vaccine recipients (n p 35) 18 (51.4)a — 11 (31.4)b 7 (20.0)
Control subjects (n p 33) 25 (75.8) — 18 (54.5) 7 (21.2)
Reduction, % (P) 32.1 (.06) — 42.4 (.09) 5.6 (.85)
NOTE. Data are no. (%) of patients, unless otherwise specified.
a Comparison of groups vaccinated before and during influenza season, .Pp .01
b Comparison of groups vaccinated before and during influenza season, .Pp .02
with respect to the epidemiological variables likely to influence
the recurrence of AOM.
All of the vaccine recipients received the 2 doses at the sched-
uled times. Sixty-five (97%) of 67 vaccine recipients completed
the study; 2 (3.0%) were given chemoprophylaxis after 6 and
19 weeks. The study was completed by 61 (92.4%) of 66 control
subjects; 5 (7.6%) required chemoprophylaxis after 8, 9, 10,
11, and 16 weeks. The overall follow-up period, therefore, was
1637 patient-weeks for the vaccine recipients and 1567 patient-
weeks for the control subjects.
Rates of febrile respiratory illness, AOM, and antibiotic
use. Table 2 lists the occurrence of febrile respiratory illnesses,
AOM episodes, and antibiotic administration during the study
period; the rates for all these events were significantly lower for
the group of vaccine recipients. Twenty-four vaccine recipients
had 32 episodes of AOM, whereas 42 control subjects had 64
episodes. No patient experienced a relapse. The mean number
of episodes per patient was twice as high in the control group
as in the vaccine recipient group (0.97 vs. 0.48 episodes per
patient). In comparison with the 6 months preceding enroll-
ment, there was a substantial reduction in the mean rate of
occurrence of AOM in both groups: from 0.53 to 0.08 episodes
per patient among vaccine recipients and from 0.55 to 0.17
episodes per patient among control subjects.
The overall efficacy of vaccination for prevention of AOM
was 43.7% (95% CI, 18.6–61.1). Its efficacy for prevention of
1 episode during the 6-month study was 31.8% (95% CI,
11.9–58.45) and reached 63.1% (95% CI, 11.43–84.59) for pre-
vention of 2 episodes during the study period.
Occurrence of AOM in relation to the influenza season.
Table 3 shows data on the occurrence of AOM in relation to
the time of enrollment and the influenza season, which lasted
from 10 December 1999 until 28 February 2000. The predom-
inant influenza virus was A/H3N2, with very few H1N1 or type
B isolates [23]. Sixty-five (48.9%) of 133 children (32 vaccine
recipients and 33 control subjects) were enrolled before the
influenza season and 68 children (51.1%; 35 vaccine recipients
and 33 control subjects) after the onset of influenza season.
The rate of AOM was always lower among vaccine recipients
than among control subjects, regardless of the time of enroll-
ment, but this difference was statistically significant only if the
period before influenza season was considered. Among the vac-
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Table 4. Occurrence of acute otitis media in relation to epidemiological






(n p 66) P
Age
12–24 months 8/27 (29.6) 13/22 (59.1) .07
25–60 months 16/40 (40.0) 29/44 (65.9) .03
Sex
Male 12/38 (31.6) 23/42 (54.8) .06
Female 12/29 (41.4) 19/24 (79.2) .01
Day care attendance
Yes 19/50 (38.0) 34/54 (63.0) .01
No 5/17 (29.4) 8/12 (66.7) .10
Passive exposure to smoking
Yes 7/10 (70.0) 6/9 (66.7) 1.00
No 17/57 (29.8) 36/57 (63.2) .0007
NOTE. Data are no. of patients with factor/no. in the subgroup (%). P value is for the
comparison of vaccine recipients and control subjects for each subgroup.
Table 5. Occurrence of clinical adverse events during the 4
days after administration of each dose of influenza vaccine to
children.
Adverse event








Rectal temperature 38.1C 6 (9.0) 2 (3.0)
Shivering 4 (6.0) 5 (7.5)
Irritability 12 (17.9) 17 (25.4)
Earache 5 (7.5) 7 (10.4)
Nausea 1 (1.5) 2 (3.0)
Diarrhea 2 (3.0) 3 (4.5)
Coughing 29 (43.3) 19 (28.4)
1 systemic event 36 (53.7) 33 (49.3)
Local events
Irritation 7 (10.4) 7 (10.4)
Sneezing 20 (29.9) 19 (28.4)
Stuffy nose 29 (43.3) 22 (32.8)
Runny nose 29 (43.3) 27 (40.3)
1 local event 43 (64.2) 33 (49.3)
NOTE. Differences were NS.
cine recipients, AOM was less frequent among those vaccinated
before than among those vaccinated after the beginning of the
influenza season; this difference was statistically significant for
the follow-up period as a whole (6 [18.8%] of 32 patients vs.
18 [51.4%] of 35; ), and for the period during thePp .01
influenza epidemic (2 [6.3%] of 32 patients vs. 11 [31.4%] of
35; ), but not for the period after the influenza seasonPp .02
(2 [6.3%] of 32 patients vs. 7 [20%] of 35; ).Pp .15
Occurrence of AOM in the epidemiological subgroups. As
shown in table 4, the rate of occurrence of AOM in the epi-
demiological subgroups was always lower among the vaccine
recipients, but this difference was significant only for the sub-
groups of children older than 24 months, girls, children at-
tending day care centers, and children not passively exposed
to smoking. The stepwise logistic analysis demonstrated that
there were no statistically significant interactions between any
of the subject characteristics and the method of treatment. In
addition to the method of treatment, only passive exposure to
smoking influenced outcome (OR, 3.0; 95% CI, 1.01–9.0).
Persistence of OME. By the end of the 6-month period,
the proportion of children with OME had declined in both
groups: 26 (40.0%) of 65 vaccine recipients had bilateral OME,
11 (16.9%) had unilateral OME, and 28 (43.1%) were free of
effusion. Among control subjects, 35 (57.4%) of 61 had bilateral
OME, 15 (24.6%) had unilateral OME, and 11 (18.0%) were
free of effusion. The proportion of children free of effusion is
statistically significant ( ). The cumulative duration ofPp .004
bilateral effusion, expressed as a percentage of the total number
of patient-weeks, was significantly different in the 2 groups:
58.0% (949 of 1637 patient-weeks) for the vaccine recipient
group and 74.5% (1168 of 1567) for the control group (P !
)..0001
Safety. Table 5 summarizes data on adverse events that
occurred in the 4 days after administration of each dose and
that were judged to be possibly (even if remotely) related to
the vaccine, which was generally well tolerated by the children,
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regardless of their age. No serious adverse events were reported.
After administration of the first dose, two-thirds of the children
experienced 1 local symptoms, and ∼50% experienced 1
systemic symptom. The majority of the adverse events were
transient (lasting 1–2 days) and mild to moderate in severity.
Cough was the most common systemic event, followed by ir-
ritability. A runny or stuffy nose was the most frequently re-
ported local symptom. The proportion of children with symp-
toms was lower after the second dose, but not significantly so.
The parents of 66 (98.5%) of 67 children were satisfied with
the vaccine (13 [19.4%] of 67 rated it “very good” and 53
[79.1%] of 67 rated it “good”).
DISCUSSION
Our results indicate that in children with recurrent AOM, the
intranasal, inactivated, virosomal subunit influenza vaccine en-
hances the natural time-linked decline in the occurrence of new
episodes of AOM. In fact, the vaccine was associated with a
further 43.7% reduction in the number of episodes of AOM
during the 6-month follow-up period. The efficacy of the vac-
cine was greater than that reported in earlier studies of par-
enteral inactivated [9, 10] and intranasal live-attenuated [12,
13] influenza vaccines. One possible reason is that our study
involved selected children with a recent history of recurrent
AOM, in whom, as has been demonstrated for pneumococcal
vaccine [24], vaccine efficacy may be greater than in children
not prone to otitis. It is worth noting that the vaccine inter-
rupted long-term recurrences of AOM: its efficacy in reducing
the number of episodes was greatest after the occurrence of the
first episode.
As reported by Belshe et al. [12, 13], we also observed a
reduction in the number of febrile respiratory illnesses and in
the amount of antibiotic consumption in the vaccinated group.
Even in the absence of virological diagnoses, but considering
the prevalent circulation of type A strain, these findings suggest
that the vaccine-induced prevention of influenza also leads to
the prevention of both AOM and other respiratory infections,
in accordance with the finding that influenza A virus infection
in the nasopharynx is associated with enhanced bacterial col-
onization and infection [25, 26].
Our study could be criticized because it was not a double-
blind, placebo-controlled study. However, we think that the
absence of a placebo was compensated for by 2 facts: first, all
the parents were contacted twice per week to inquire about
day-to-day status and to remind them of the possibility of freely
contacting an investigator; and second, they were instructed at
study entry and reminded at each visit not to discuss group
assignment with the single investigator responsible for otolog-
ical follow-up.
The timing of the administration of influenza vaccine has
an important effect on its efficacy against AOM. Although all
of the vaccine recipients experienced fewer AOM episodes than
did the control subjects, the children vaccinated before the start
of influenza season had significantly better outcomes through-
out the follow-up period than did children vaccinated during
the influenza season. Therefore, the vaccination of children with
recurrent AOM should be carefully planned to complete the
administration of vaccine doses before the estimated onset of
the influenza season.
To our knowledge, this is the first study to evaluate the
influence of epidemiological variables on the efficacy of influ-
enza vaccine against recurrent AOM. The intranasal virosomal
influenza vaccine was more effective in children aged 2–5 years
than in younger children, and although the lack of significance
for the findings in the latter group may be related to the small
size of the sample, the results for the former group are of
particular interest in clinical practice, because antibiotic pro-
phylaxis was shown to be less effective in this age group [27,
28]. The finding that influenza vaccine was more effective in
children attending day care centers is in agreement with our
previous studies of chemoprophylaxis [27, 28] and supports
the hypothesis that prevention is more effective for children
with1 of the known risk factors for recurrent AOM. However,
the fact that the vaccine was of no relevant benefit to children
passively exposed to smoking suggests that its advantages are
at least neutralized in the presence of such a strong risk factor
[29]. Finally, we are unable to interpret the fact that the vaccine
was more effective in girls.
The intranasal virosomal influenza vaccine substantially re-
duced the persistence of middle ear effusion. The proportion
of children without OME at the end of the study period and
the cumulative duration of bilateral OME were significantly less
for the vaccine recipient group. This findings is in agreement
with the results of Clements et al. [10], who found a 28%
reduction in the incidence of OME during the influenza season
among children who were given inactivated influenza vaccine,
but it contrasts with our own findings concerning chemopro-
phylaxis [27, 28], which showed that long-term low-dosage
antibiotic administration had no significant effect on the nat-
ural history of OME. Our findings for the vaccine recipients
can be explained by the reduction in the number of episodes
of AOM and of febrile respiratory illnesses, both of which are
known to be strictly related to eustachian tube dysfunction and,
therefore, to the persistence of OME [30].
Although approximately one-half of the vaccine recipients
experienced at least 1 adverse event, the vaccine was generally
well tolerated. The adverse events were predominantly mild
and transient; they usually resolved within 24–48 h. Because a
placebo was not used in the study, the parents’ knowledge that
the vaccine was administered may have led to some excess
reporting, but the prevalences of both local and systemic re-
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actions were quite similar to those reported previously for the
same vaccine in adults [20]. Moreover, the scanty clinical rel-
evance of the vaccine-related adverse effects is supported by
the parents’ overall satisfaction with the vaccine.
In conclusion, provided that timing is appropriate, our data
suggest that the intranasal inactivated virosomal influenza vac-
cine might be considered among the options for the prevention
of new AOM episodes in children !5 years old with recurrent
AOM.
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